(RTTNews) - Mirae Asset Securities (00680K.KS) reported that its first quarter net income attributable to shareholders of the parent company came to 996.25 billion Korean won, up 285.0% compared to the same quarter last year. Operating income was 1.38 trillion Korean won, reflect
(RTTNews) - Mirae Asset Securities (00680K.KS) reported that its first quarter net income attributable to shareholders of the parent company came to 996.25 billion Korean won, up 285.0% compared to the same quarter last year. Operating income was 1.38 trillion Korean won, reflect
When a 52-year-old Indonesian woman approached her saying she was broke and needed a place to stay, Lim felt sorry for her. Out of sympathy, the 29-year-old Malaysian rented out her flat in Ampang, Kuala Lumpur, to the Indonesian without signing any formal tenancy agreement in March last year. Now, she is full of regret. Lim said the tenant had used the flat address to secure loans and loan sharks...
When a 52-year-old Indonesian woman approached her saying she was broke and needed a place to stay, Lim felt sorry for her. Out of sympathy, the 29-year-old Malaysian rented out her flat in Ampang, Kuala Lumpur, to the Indonesian without signing any formal tenancy agreement in March last year. Now, she is full of regret. Lim said the tenant had used the flat address to secure loans and loan sharks are now harassing the house owner. “The loan sharks threatened to burn down the house and splash...
SOMKID THONGDEE/iStock via Getty Images The following segment was excerpted from the McIntyre Partnerships Q1 2026 Partners Letter. Life Science and Diagnostic Tools Sector Before I dive into QDEL, I want to briefly highlight the overall move in life science and diagnostics tools YTD: Q1 End Jan Peak Jan peak vs. 3/31/2026 ABT -19% 2% -21% AVTR -32% 12% -39% BRKR -23% 15% -33% DHR -15% 6% -20% ILM...
SOMKID THONGDEE/iStock via Getty Images The following segment was excerpted from the McIntyre Partnerships Q1 2026 Partners Letter. Life Science and Diagnostic Tools Sector Before I dive into QDEL, I want to briefly highlight the overall move in life science and diagnostics tools YTD: Q1 End Jan Peak Jan peak vs. 3/31/2026 ABT -19% 2% -21% AVTR -32% 12% -39% BRKR -23% 15% -33% DHR -15% 6% -20% ILMN -6% 17% -20% MTD -9% 7% -15% SRT3 -15% 7% -21% TMO -14% 10% -22% WAT -21% 6% -25% QGEN -13% 23% -29% RVTY -8% 22% -25% BIM FP -17% 5% -21% -- Average -16% 11% -24% QDEL -40% 24% -52% Click to enlarge The life science tools space has broadly declined amid fears that AI models will dramatically change how drugs are developed. I think we are a ways away from anyone being injected with a drug made entirely from asking ChatGPT with no further testing, and QDEL specifically has almost nothing to do with drug development, but when blue chip stocks in your sector like ABT, TMO, and DHR are all down 15-20%, it's hard to fight that trend. My point here is not to pontificate and make a sector bet, so much as to point out that neither the January rally in QDEL nor the significant decline since then is happening in a vacuum. I do not think AI will fundamentally replace anything in QDEL's model any time soon. If the comp group begins to recover, as the stocks are beginning to in May, I think it is a favorable backdrop for our investment. Thesis QDEL is a healthcare diagnostics tools company focused on routine blood testing, primarily at hospitals and central labs, and point-of-care (POC) respiratory testing. Its business is a razor/razor blade model, where machines are sold or leased up front for minimal cost (i.e., "the razor"), and then customers commit to purchase consumables at high gross margins (the "razor blades"). ~95% of sales are consumables. In the labs and immunochemistry businesses, which account for over 75% of sales, customers sign 5-7-year contracts, and the company boa...
According to a recent SEC filing dated May 11, 2026, PCJ Investment Counsel liquidated its entire holding in Methanex (NASDAQ:MEOH) , by selling 208,630 shares. The estimated transaction value is $10.50 million based on the average closing price during the first quarter. The fund held no Methanex shares at the end of the period, and the position value dropped by $8.28 million from the previous qua...
According to a recent SEC filing dated May 11, 2026, PCJ Investment Counsel liquidated its entire holding in Methanex (NASDAQ:MEOH) , by selling 208,630 shares. The estimated transaction value is $10.50 million based on the average closing price during the first quarter. The fund held no Methanex shares at the end of the period, and the position value dropped by $8.28 million from the previous quarter. Methanex is a leading global methanol producer with a diversified geographic footprint and integrated logistics capabilities. The company leverages its scale and operational expertise to supply methanol to industrial customers worldwide. Strategic control of production and distribution assets supports Methanex's competitive positioning in the chemicals sector. When an institution sells its entire holdings of a company, investors often take notice. Recently, PCJ Investment Counsel exited its Methanex (MEOH) positions. We can only speculate about its reasons for doing so, but there are a few possibilities to note. Continue reading